Prostate News Archive
04-Apr-2007
Study: Hold off hormone therapy for prostate cancer (Arizona Daily Star)
Treating progressive prostate cancer early with therapy that blocks male hormones doesn't improve survival, and doctors should delay the treatment, according to new practice guidelines from a U.S. cancer-physicians group. Hormone Therapy for Advanced Prostate Cancer Not for Everyone (HealthDay via Yahoo! News)
MONDAY, April 2 (HealthDay News) -- For men with advanced prostate cancer, starting hormone therapy quickly comes with benefits and risks that may -- in some cases -- cancel each other out, according to new guidelines issued by the American Society of Clinical Oncology. Cell Genesys shares soar on positive GVAX prostate trial data (Market Watch)
BOSTON (MarketWatch) -- Shares of Cell Genesys Inc. rallied Monday, a move higher precipitated by positive research data for GVAX, the biotechnology company's prostate-cancer drug therapy. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer (PR Newswire via Yahoo! Finance)
Cell Genesys, Inc. today announced final, updated results from its second multi-center Phase 2 trial of GVAX immunotherapy for prostate cancer which evaluated escalating doses of the immunotherapy in 80 patients with metastatic hormone-refractory prostate cancer .
Back to Prostate News Archive
